

66/11/10



S 0 568

App

C

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

GAU 1615#

#7
DW
1/16/99

Applicants: David A. Edwards, Robert S. Langer, Rita Vanbever, Jeffrey Mintzes, Jue Wang, and Donghao Chen

Serial No.: 08/971,791 Art Unit: 1615

Filed: November 17, 1997 Examiner: K. Shelbourne

For: *Preparation of Particles for Inhalation*Assistant Commissioner for Patents
Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT

Sir:

Pursuant to 37 C.F.R. §1.56 and 37 C.F.R. §1.97, Applicants submit an Information Disclosure Statement, including sixteen (16) pages of Form PTO-1449 and copies of the documents cited therein. Copies of the documents marked with an asterisk (*) will be filed in a Supplemental Information Disclosure Statement.

Enclosed is a check for \$240.00 representing the fee required under 37 C.F.R. § 1.17(p) for an Information Disclosure Statement filed after a first office action on the merits under 37 C.F.R. §1.97(c). It is believed that no additional fee is required with this submission. However, should a fee be required, the Assistant Commissioner is authorized to charge any fees to Deposit Account No. 01-2507.

US Patents

Number	Issue Date	Patentee	Class/Subclass
2,470,296	5/17/49	Fields	128/266
2,533,065	3/8/47	Taplin, et al	167/65
2,992,645	7/18/61	Fowler	128/208
3,781,230	12/25/73	Vassiliades, et al	260/2.5
3,957,965	04/18/76	Hartley, et al.	424/14
4,009,280	02/22/77	Macarthur, et al.	424/283

TECHNICAL INFORMATION CENTER
11/13/1999 8:50:00 AM
11/13/1999 8:50:00 AM788703v1
MiT 7513/7804
20220/462

4,089,800	04/16/78	Temple	252/316
4,161,516	07/17/79	Bell	424/14
4,173,488	11/06/79	Vassiliades, et al.	106/213
4,272,398	06/09/81	Jaffe	252/316
4,352,883	10/05/82	Lim	435/178
4,391,909	07/05/83	Lim	435/178
4,466,442	08/21/84	Hilmann, et al.	128/653
4,524,769	06/25/85	Wetterlin	123/203.15
4,572,203	02/25/86	Feinstein	128/661
4,590,206	05/20/86	Forrester, et al.	514/456
4,615,697	10/07/86	Robinson	604/890
4,679,555	07/14/87	Sackner	128/203.15
4,741,872	04/03/88	De Luca, et al.	264/4.7
4,743,545	05/10/88	Torobin	435/41
4,774,958	10/04/88	Feinstein	128/660.01
4,789,550	12/06/88	Hommel, et al.	424/493
4,818,542	04/04/89	DeLuca, et al.	424/491
4,847,091	07/11/89	Illum	424/455
4,855,144	08/08/89	Leong, et al.	424/487
4,857,311	08/15/89	Domb, et al.	424/78
4,861,627	08/29/89	Mathiowitz, et al	427/213.31
4,865,789	09/12/89	Castro, et al.	264/122
4,904,479	02/27/90	Illum	424/490
4,917,119	04/17/90	Potter, et al.	131/273
4,976,968	12/11/90	Steiner	424/491
4,994,281	02/19/91	Muranishi, et al.	424/497
5,033,463	07/23/91	Cocozza	128/203.21
5,064,0650	11/12/91	Lew	424/435
5,069,936	12/03/91	Yen	427/213.33
5,075,109	12/24/91	Tice, et al.	424/88
5,100,669	03/31/92	Hyon, et al.	424/4265
5,123,414	06/23/92	Unger	128/654
5,160,745	11/03/92	DeLuca, et al.	424/487
5,169,871	12/08/92	Hughes, et al.	521/64
5,195,520	03/23/93	Schlief, et al.	128/660.02
5,204,108	04/20/93	Illum	424/434
5,204,113	04/20/93	Hartley, et al.	424/45
5,260,306	11/09/93	Boardman, et al.	514/291
5,271,961	12/21/93	Mathiowitz, et al.	427/213.31
5,327,883	07/12/94	Williams, et al.	128/203.12
5,334,381	08/02/94	Unger	424/9
5,352,435	10/04/94	Unger	424/9
5,384,133	01/24/95	Boyes, et al.	424/501
5,393,524	02/28/95	Quay	424/9
5,407,609	04/18/95	Tice, et al.	264/46
5,456,917	10/10/95	Wise, et al.	424/426



U.S.S.N.: 08/971,791
Filed: November 17, 1997
Information Disclosure Statement

5,482,946	01/09/96	Clark, et.al.	01/09/96
5,518,709	04/21/96	Sutton, et al.	424/9.52
5,607,695	03/04/97	Ek, et al.	424/468
5,612053	03/18/97	Baichwal, et al	424/468

Foreign Documents

<u>Number</u>	<u>Date</u>	<u>Country</u>
0 072 046	02/16/83	EPA
0 213 303	06/23/86	EPA
0 257 915	03/02/88	EP
0 324 938	07/26/89	EPA
0 458 745	05/14/91	EPA
0 335 133	10/04/89	EP
1 288 583	11/17/69	GB
WO 80/02365	11/13/80	PCT
WO 88/04556	06/30/88	PCT
WO 88/09163	12/01/88	PCT
WO 91/04732	04/18/91	PCT
WO 91/06287	05/16/91	PCT
WO 91/06286	05/16/91	PCT
WO 91/12823	09/05/91	PCT
WO 92/18164	10/29/92	PCT
WO 92/21382	12/10/92	PCT
WO 93/25221	12/23/93	PCT
WO 94/08627	04/28/94	PCT
WO 94/16739	04/04/94	PCT
WO 94/07514	04/14/94	PCT
WO 95/00127	01/05/95	PCT
WO 95/24183	09/14/95	PCT
WO 95/07072	03/16/95	PCT
WO 96/09814	04/04/96	PCT
WO 96/15814	05/30/96	PCT
WO 97/36574	10/09/97	PCT

Publications

Adjei and Garren, "Pulmonary Delivery of Peptide Drugs: Effect of Particle Size on Bioavailability of Leuprolide Acetate in Healthy Male Volunteers," *J. Pharm. Res.*, 7(6): 565-569 (1990).

Allen, et al. "Subcutaneous administration of liposomes: a comparison with the intravenous and intraperitoneal routes of injection" *Biochim. Biophys. Acta* 1150: 9-16 (1993).

Altschuler et al., "Aerosol deposition in the human respiratory tract," *Am. Med. Assoc. Arch. Indust. Health* 15:293-303 (1957).

Anderson et al., "Effect of Cystic Fibrosis on Inhaled Aerosol Boluses," Am. Rev. Respir. Dis., 140: 1317-1324 (1989).

Anderson, "Human Deposition and Clearance of 6 micrometer Particles Inhaled with an Extremely Low Flow Rate" Exp. Lung Res. 21(1): 187-195 (1995)

* Barrera et al., "Synthesis and RGD Peptide Modification of a New Biodegradable Copolymer: Poly(lactic acid-co-lysine)," J. Am. Chem. Soc., 115:11010 (1993).

Beck, et al.. "A new Long-Acting Injectable Microcapsule System for the Administration of Progesterone", Fertility and Sterility 31(5): 545-551 (1979).

Benita et al., "Characterization of drug-loaded poly(d,l-lactide) microspheres," J. Pharm. Sci. 73, 1721-1724 (1984).

Blackett and Buckton, "A Microcalorimetric Investigation of the Interaction of Surfactants with Crystalline and Partially Crystalline Salbutamol Sulphate in a Model Inhalation Aerosol System," Pharmaceutical Research 12(11):1689-1693 (1995).

Brain, "Physiology and Pathophysiology of Pulmonary Macrophages," in The Reticuloendothelial System, Reichard and Filkins, Eds., Plenum Press, New York, pp. 315-327 (1985).

Brown, et al. "Propellant-driven aerosols of functional proteins as potential therapeutic agents in the respiratory tract" Immunopharmacology 28:241-257 (1994)

Byron, "Determinants of drug and polypeptide bioavailability from aerosols delivered to the lung," Adv. Drug. Del. Rev., 5: 107-132 (1990)

Carroll, et al. "Gelatin Encapsulated Nitrogen Microbubbles as Ultrasonic Contrast Agents" Investigative Radiology 15: 260-266 (1980).

Carroll, et al. "Ultrasonic Contrast Enhancement of Tissue by Encapsulated Microbubbles" Radiology 143:747-750 (1982).

Ch'ng, et al. :Bioadhesive Polymers as Platforms for Oral Controlled Drug Delivery II: Synthesis and Evaluation of Some Swelling, Water-Insoluble Bioadhesive Polymers" J. Pharm. Sci. 74(4):399-405 (1985).

Clark, et al. "Dependence of Pulmonary Absorption Kinetics on Aerosol Particle Size" Zeitschrift fur Erkankungen der Atmungsorgane 166: 13-24 (1986).

Clark and Egan, "Modeling the deposition of inhaled powdered drug aerosols," J. Aerosol Sci., 25:175-186 (1994).

U.S.S.N.: 08/971,791
Filed: November 17, 1997
Information Disclosure Statement

Clay et al., "Effect of aerosol particle size on bronchodilation with nebulized terbutaline in asthmatic subjects," Thorax 41:364-368 (1986).

Cohen et al., "Controlled Delivery Systems for Proteins Based on Poly(Lactic/Glycolic Acid) Microspheres," Pharm. Res., 8(6): 713-720 (1991).

Colthorpe et al., "The Pharmacokinetics of Pulmonary-Delivered Insulin: A Comparison of Intratracheals and Aerosol Administration to the Rabbit," Pharm. Res. 9:764 (1992).

Daly et al., "The Preparation of N-Carboxyanhydrides of α -Amino Acids Using Bis(Trichloromethyl)Carbonate," Tetrahedron Lett., 29:5859 (1988).

Damms and Bains, "The Cost of Delivering Drugs without Needles," J. Controlled Release, 8-11 (1996).

Darquenne, et al. "Two and three-dimensional simulations of aerosol transport and deposition in alveolar zone of human lung" Journal of Applied Physiology Davies et al., "Breathing of half-micron aerosols. I. Experimental," J. Appl. Physiol. 32:591-600 (1972).

Davies, et al "Breathing of half-micron aerosols I. Experimental" J. App. Physiol. 32: 591-600 (1972).

Davis, et al. "Polymeric microspheres as drug carriers" Biomaterials 9:111-115 (1988).

Davis, et al. "Microspheres as Controlled Release Systems for Parenteral and Nasal Administration", Controlled Release Technology Chapter 15, pp 201-213 (1987).

Dorries and Valberg, "Heterogeneity of phagocytosis for inhaled versus instilled material," Am. Rev. Resp. Disease, 146: 831-837 (1991).

* Doubrow, M., Ed., "Microcapsules and Nanoparticles in Medicine and Pharmacy," CRC Press, Boca Raton, (1992).

Edwards, et al. "Large Porous Particles for Pulmonary Drug Delivery" Science, 276: 1868-71 (1997).

Edwards, "The macrotransport of aerosol particles in the lung: Aerosol deposition phenomena," J. Aerosol Sci., 26: 293-317 (1995)

Eldridge et al., "Biodegradable microspheres as a vaccine delivery system," Mol. Immunol., 28: 287-294 (1991).

Feinstein, et al. "Two-Dimensional Contrast Echocardiography. I. In Vitro Development and Quantitative Analysis of Echo Contrast Agents" JACC 3(1): 14-20 (1984).

U.S.S.N.: 08/971,791
Filed: November 17, 1997
Information Disclosure Statement

Ferin, "Pulmonary Retention of Ultrafine and Fine Particles in Rats" Am. J. Respir. Cell Mol. Biol. 6: 535-542 (1992).

Findeisen, "Uber das Absetzen kleiner in der Luft suspendierter Teilchen in der menshlichen Lunge bei der Atmung," Pflugers Arch. D. Ges. Physiol. 236:367-379 (1935).

French, Edwards, and Niven, "The influence of formulation on emission, deaggregation and deposition of dry powders for inhalation," J. Aerosol Sci., 27: 769-783 (1996).

Ganderton, "The generation of respirable clouds from coarse powder aggregates," J. Biopharmaceutical Sciences, 3:101-105 (1992).

Gehr et al., "Surfactant and inhaled particles in the conducting airways: Structural, stereological, and biophysical aspects," Microscopy Res. and Tech., 26: 423-436 (1993).

Gerrity et al., "Calculated deposition of inhaled particles in the airway generations of normal subjects," J. Appl. Phys., 47:867-873 (1979).

Gonda, "Aerosols for delivery of therapeutic and diagnostic agents to the respiratory tract," in Critical Reviews in Therapeutic Drug Carrier Systems 6:273-313 (1990).

Gonda, "Preface. Major issues and future prospects in the delivery of therapeutic and diagnostic agents to the respiratory tract," Adv. Drug Del. Rev., 5: 1-9 (1990).

Gonda, "Physico-chemical principles in aerosol delivery," in Topics in Pharmaceutical Sciences 1991, Crommelin, D.J. and K.K. Midha, Eds., Medpharm Scientific Publishers, Stuttgart, pp. 95-117, 1992.

Gonda, "Targeting by deposition," in Pharmaceutical Inhalation Aerosol Technology (ed. A.J. Hickey), Marcel Dekkar Inc., New York, 1992.

Gurny, et al. Bioadhesive intraoral release systems: design, testing and analysis" Biomaterials 5: 336-340 (1984)

Heyder et al., "Deposition of Particles in the Human Respiratory Tract in the Size Range 0.005-15 micrometers," J. Aerosol Sci., 17: 811-825 (1986).

Heyder and Rudolf, "Mathematical models of particle deposition in the human respiratory tract," J. Aerosol Sci., 15:697-707 (1984).

Heyder et al., "Total Deposition of Aerosol Particles in the Human Respiratory Tract for Nose and Mouth Breathing," J. Aerosol Sci., 6:311-328 (1975).

Hickey et al., "Use of particle morphology to influence the delivery of drugs from dry powder aerosols," J. Biopharmaceutical Sci., 2(1/2):107-113 (1992).

U.S.S.N.: 08/971,791
Filed: November 17, 1997
Information Disclosure Statement

Hirano et al, "Pulmonary clearance and Toxicity of Zinc Oxide Instilled into the Rat Lung," Toxicology 63:336-342 (1989).

Hrkach et al., "Synthesis of Poly(L-lactic acid-co-L-lysine) graft copolymers," Macromolecules, 28:4736-4739 (1995).

Hrkach et al., "Poly(L-Lactic acid-co-amino acid) Graft Copolymers: A Class of Functional Biodegradable Biomaterials" in Hydrogels and Biodegradable Polymers for Bioapplications, ACS Symposium Series No. 627, Raphael M. Ottenbrite et al., Eds., American Chemical Society, Chapter 8, pp. 93-101, 1996.

Illum, "Bioadhesive microspheres as a potential nasal drug delivery system" Int. J Pharm. 39: 189-199 (1987).

Illum, " Microspheres as a Potential Controlled Release Nasal Drug Delivery System," Delivery Systems for Peptide Drugs, NY: Plenum, 1986.

Johnson et al., "Delivery of Albuterol and Ipratropiumbromide from Two Nebulizer Systems in Chronic Stable Asthma," Chest, 96, 6-10, 1989.

Kao, et al. "Interactions of liposomes with the Reticuloendothelial System" Biochim. Biophys. Acta 677: 453-461 (1981)

Kassem and Ganderton, "The Influence of Carrier Surface on the Characteristics of Inspirable Powder Aerosols," J. Pharm. Pharmacol., 42 (Supp):11 (1990).

Kawaguchi et al., "Phagocytosis of latex particles by leukocytes. I. Dependence of phagocytosis on the size and surface potential of particles," Biomaterials 7: 61-66 (1986).

Kobayashi et al., "Pulmonary Delivery of Salmon Calcitonin Dry Powders Containing Absorption Enhancers in Rats," Pharm. Res., 13(1): 80-83 (1996).

Kohler, "Aerosols for Systemic Treatment" Lung Suppl: 677-684 (1990).

Komada et al., "Intratracheal Delivery of Peptide and Protein Agents: Absorption from Solution and Dry Powder by Rat Lung," J. Pharm. Sci. 83(6):863-867 (June, 1994).

Krenis and Strauss, "Effect of Size and Concentration of Latex Particles on Respiration of Human Blood Leucocytes," Proc. Soc. Exp. Med., 107:748-750 (1961).

Kricheldorf, H. R. in *Models of Biopolymers by Ring-Opening Polymerization*, Penczek, S., Ed., CRC Press, Boca Raton, 1990, Chapter 1;

Kricheldorf, H. R. *α -Aminoacid-N-Carboxy-Anhydrides and Related Heterocycles*, Springer-Verlag, Berlin, 1987.

U.S.S.N.: 08/971,791
Filed: November 17, 1997
Information Disclosure Statement

Kwok, et al. "Production of 5-15 micrometer Diameter Alginate Polylysine Microcapsules by an Air-Atomization Technique," Pharm Res. 8(3):341-344 (1991).

Lai, et al. "Protection Against Mycoplasma pulminosis Infection by Genetic Vaccination" DNA and Cell Biology 14(7): 643-651 (1995).

Lai et al., "Sustained bronchodilation with isoproterenol poly(glycolide-co-lactide) microspheres," Pharm. Res., 10(1) 119-125 (1993).

Landahl, "On the removal of air-borne droplets by the human respiratory tract: I. The lung," Bull. Math. Biophys., 12:43-56 (1950).

Langer, "New Methods of Drug Delivery," Science, 249:1527-1533 (1990).

LeCorre et al., Preparation and characterization of bupivacaine-loaded polylactide and polylactide-co-glycolide microspheres," Int. J. Pharmaceutics, 107:41-49 (1994).

Leone-Bay et al., "Microsphere formation in a series of derivatized α -amino acids: Properties, molecular modeling and oral delivery of salmon calcitonin," J. Med. Chem., 38:4257-4262 (1995).

Liu et al., "Pulmonary Delivery of Free and Liposomal Insulin," Pharm. Res. 10(2):228 -232 (1993).

Liu et al., "Moisture-induced aggregation of lyophilized proteins in the solid state," Biotechnol. Bioeng., 37: 177-184 (1991).

Martonen, "Mathematical model for the selective deposition of inhaled pharmaceuticals", J. Pharm. Sci., 82(12):1191-1198 (1993).

Masinde and Hickey, "Aerosolized aqueous suspensions of poly(L-lactic acid) microspheres," Int. J. Pharmaceutics, 100:123-131 (1993).

Mathiowitz et al., "Novel microcapsules for delivery systems," Reactive Polymers 6, 275-283 (1987).

Mathiowitz et al., "Polyanhydride microspheres. IV. Morphology and characterization of systems made by spray drying," J. Appl. Polymer Sci. 45, 125-134 (1992).

Mathiowitz et al., "Morphology of polyanhydride microsphere delivery systems," Scanning Microscopy 4: 329-340 (1990).

Mathiowitz and Langer, "Polyanhydride Microspheres as Drug Carriers I. Hot-Melt Microencapsulation," J. Controlled Release 5,13-22 (1987).

U.S.S.N.: 08/971,791
Filed: November 17, 1997
Information Disclosure Statement

Mathiowitz et al., "Polyanhydride microspheres as drug carriers. II. Microencapsulation by solvent removal," J. Appl. Polymer Sci. 35, 755-774 (1988).

Menache, et al. "Particle Inhalability Curves for Humans and Small Laboratory Animals" Annals of Occupational Hygiene 39(3): 317-328 (1995).

Moren, "Aerosol dosage forms and formulations," in: *Aerosols in Medicine. Principles, Diagnosis and Therapy*, Moren, et al., Eds, Elsevier, Amsterdam, 1985.

Morimoto and Adachi, "Pulmonary Uptake of Liposomal Phosphatidylcholine Upon Intratracheal Administration to Rats," Chem. Pharm. Bull. 30(6):2248-2251 (1982).

Mulligan, "The Basic Science of Gene Therapy," Science, 260: 926-932 (1993).

Mumenthaler et al., "Feasibility Study on Spray-Drying Protein Pharmaceuticals: Recombinant Human Growth Hormone and Tissue-Type Plasminogen Activator," Pharm. Res., 11: 12-20 (1994).

Newman, "Therapeutic inhalation agents and devices" Postgraduate Medicine 76(5):194-207 (1984).

Newman, "Aerosol Deposition Considerations in Inhalation Therapy" Chest 88(2) 153-160 (1985).

* New, R.R.C., "Characterization of Liposomes," in *Liposomes: A Practical Approach*, R. New, Editor, IRL Press, New York, 105-161 (1990).

Niven, et al. "Solute Absorption from the Airways of the Isolated Rat Lung. III. Absorption of Several Peptidase-Resistant, Synthetic Polypeptides: Poly-(2-Hydroxyethyl)-Aspartamides" Pharm. Res., 7(10) 990-994 (1990).

Niven et al., "The Pulmonary Absorption of Aerosolized and Intratracheally Instilled rhG-CSF and monoPEGylated rhG-CSF," Pharm. Res., 12(9): 1343-1349 (1995).

Niwa, et al. "Aerosolization of lactice-glycolide copolymer (PLGA) nanospheres for pulmonary delivery of peptide-drugs," Yakugaku Zasshi 115(9): 732-741 (1995).

Ogiwara, "Clearance and Maximum removal rate of Liposomes in Normal and Impaired Liver of Rat" Gastrenterologia Japonica 19(1) 34-40 (1984).

Okumura et al., "Intratracheal delivery of insulin. Absorption from solution and aerosol by rat lung," Int. J. Pharmaceutics, 88:63-73 (1992).

Patton and Platz, "(D) Routes of Delivery: Case Studies (2) Pulmonary delivery of peptides and proteins," Adv. Drug Del. Rev., 8: 179-196 (1992).

Patton et al., "Bioavailability of pulmonary delivered peptides and proteins: α -interferon, calcitonins and parathyroid hormones," J. Controlled Release, 28: 79-85 (1994).

* Pavia, D. "Lung Mucociliary Clearance," in *Aerosols and the Lung: Clinical and Experimental Aspects*, Clarke, S.W. and Pavia, D., Eds., Butterworths, London, 1984

* Phalen, *Inhalation Studies: Foundations and Techniques*. CRC Press (Boca Rotan, FL), 1984.

Pinkerton et al., "Aerosolized fluorescent microspheres detected in the lung using confocal scanning laser microscopy," Microscopy Res. and Techn., 26:437-443 (1993).

Rudt and Muller, "In vitro Phagocytosis Assay of Nano- and Microparticles by chemiluminescence. I. Effect of Analytical Parameters, Particle Size and Particle Concentration," J. Contr. Rel., 22: 263-272 (1992).

Rudt et al., "In vitro phagocytosis assay of nano- and microparticles by chemiluminescence. IV. Effect of surface modification by coating of particles with poloxamine and Antarox CO on the phagocytic uptake," J. Contr. Rel. 25:123 (1993).

Ruffin et al., "The Preferential Deposition of Inhaled Isoproterenol and Propanolol in Asthmatic Patients," Chest 80:904-907 (1986).

Sela et al., "Multichain Polyamino Acids," J. Am. Chem. Soc., 78:746 (1956).

Smith, et al. "Aerosol Administration of Antibiotics" Respiration, 62(1) 19-24 (1995).

Smith, "Peptide delivery via the pulmonary route: a valid approach for local and systemic delivery" J. Contr. Rel. 46: 99-106 (1997).

Strand, et al. "Radiolabeled Colloids and Macromolecules in the Lymphatic System" Critical Reviews in Therapeutic Drug Carrier Systems 6(3): 211-238 (1989).

Swift, "The oral airway - a conduit or collector for pharmaceutical aerosols?" Respiratory Drug Delivery IV, 187-194 (1994).

Tabata et al., "Controlled Delivery Systems for Proteins Using Polyanhydride Microspheres," Pharm. Res., 10(4): 487-496 (1993).

Tabata and Ikada, "Effect of surface wettability of microspheres on phagocytosis," J. Colloid and Interface Sci., 127(1): 132-140 (1989).

Tabata and Ikada, "Macrophage Phagocytosis of Biodegradable Microspheres Composed of L-lactic Acid/Glycolic Acid Homo- and Copolymers," J. Biomed. Mater. Res., 22: 837-858 (1988).

Tabata and Ikada, "Effect of size and surface charge of polymer microspheres on their phagocytosis by macrophage," J. Biomed. Mater. Res., 22:837 (1988).

Taburet, et al. "Pharmacokinetic Optimisation of Asthma Treatment" Clin. Pharmacokinet. 26(5): 396-418 (1994)

Tansey, "The challenges in the development of metered dose inhalation aerosols using ozone-friendly propellants," Spray Technol. Market, 4:26-29 (1994).

Timsina et al., "Drug delivery to the respiratory tract using dry powder inhalers," Int. J. Pharm., 101: 1-13 (1994).

Turner, J. and S. Hering, "Greased and oiled substrates as bounce-free impaction surfaces," J. Aerosol Sci., 18: 215-224 (1987).

* Vincent, Aerosol Science for Industrial Hygienists, Pergamon Press, NY (1995).

Visser, "An Invited Review: Van der Waals and Other Cohesive Forces Affecting Powder Fluidization," Powder Technology 58: 1-10 (1989).

Wall, "Pulmonary Absorption of Peptides and Proteins," Drug Delivery, 2:1-20 (1995).

Warheit and Hartsky, "Role of alveolar macrophage chemotaxis and phagocytosis in pulmonary clearance to inhaled particles: Comparisons among rodent species," Microscopy Res. Tech., 26: 412-422 (1993).

Wheatley, et al. "Contrast agents for diagnostic ultrasound: development and evaluation of polymer-coated microbubbles" Biomaterials 11: 713-717(1990).

* Weibel, Morphometry of the Human Lung, New York: Academic Press (1963).

Wichert, et al. Low molecular weight PLA: a suitable polymer for pulmonary administered microparticles?" J. Microencapsulation, 10: 195-207 (1993).

Wong and Suslick, "Sonochemically produced hemoglobin microbubbles," Mat. Res. Soc. Symp. Proc., 372:89-95 (1995).

Zanen et al., "The optimal particle size for β -adrenergic aerosols in mild asthmatics," Int. J. Pharm., 107: 211-217 (1994).

Zanen et al., "The optimal particle size for parasympatholytic aerosols in mild asthmatics" Int. J. Pharm., 114:111-115 (1995).

Zeng, et al. "Tetrandrine delivery to the lung: The optimisation of albumin microsphere preparation by central composite design" Int. J. Pharm., 109: 135-145 (1994).


Zeng et al., "The controlled delivery of drugs to the lung," Int. J. Pharm., 124:149-164 (1995).

U.S.S.N.: 08/971,791
Filed: November 17, 1997
Information Disclosure Statement

Remarks

This statement should not be interpreted as a representation that an exhaustive search has been conducted or that no better art exists. Moreover, Applicants invite the Examiner to make an independent evaluation of the cited art to determine its relevance to the subject matter of the present application. Applicants are of the opinion that their claims patentably distinguish over the art referred to herein, either alone or in combination.

Respectfully submitted,



Patrea L. Pabst
Reg. No. 31,284

Dated: January 6, 1999

ARNALL GOLDEN & GREGORY, LLP
2800 One Atlantic Center
1201 W. Peachtree Street
Atlanta, Georgia 30309-3450
(404) 873-8794
(404) 873-8795 (fax)

U.S.S.N.: 08/971,791
Filed: November 17, 1997
Information Disclosure Statement

CERTIFICATE OF MAILING (37 CFR 1.8a)

I hereby certify that this Information Disclosure Statement, along with any paper referred to as being attached or enclosed, is being deposited with the United States Postal Service on the date shown below with sufficient postage as first-class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

Date: January 7, 1999

Kristin Herring
Kristin Herring